| Nov 22 |
Citius Pharmaceuticals announces 1-for-25 reverse stock split
|
| Nov 22 |
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
|
| Nov 18 |
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
|
| Nov 11 |
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment
|
| Nov 11 |
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
|
| Sep 5 |
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 5 |
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
|
| Aug 13 |
Sidoti Events, LLC's Virtual August Micro-Cap Conference
|
| Aug 13 |
Citius merges oncology subsidiary with TenX Keane
|
| Aug 13 |
Citius Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01
|
